Truist raised the firm’s price target on Seagen (SGEN) to $229 from $152 and keeps a Hold rating on the shares. The analyst states that the current take-over by Pfizer (PFE) should have a higher likelihood of success than last year’s efforts, and while the deal will face scrutiny by the FTC, it should "ultimately pass muster".
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SGEN:
- Seagen downgraded to Equal Weight from Overweight at Morgan Stanley
- JPMorgan biotech/pharma analysts to hold analyst/industry conference call
- Seagen price target raised to $229 from $155 at RBC Capital
- Seagen price target raised to $229 from $141 at SVB Securities
- Seagen price target raised to $229 from $210 at Oppenheimer
